James J Ashton1, Gaia Andreoletti, Tracy Coelho, Rachel Haggarty, Akshay Batra, Nadeem A Afzal, R Mark Beattie, Sarah Ennis. 1. *Human Genetics and Genomic Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom; †Department of Paediatric Gastroenterology, University Hospital Southampton NHS Foundation Trust, Southampton General Hospital, United Kingdom; and ‡NIHR Nutrition Biomedical Research Centre, Southampton Centre for Biomedical Research, University Hospital Southampton NHS Foundation Trust, Southampton General Hospital, Southampton, United Kingdom.
Abstract
BACKGROUND: Most cases of inflammatory bowel disease (IBD) are caused by complex host-environment interaction. There are a number of conditions associated with a single-gene mutation, most cases are very early onset (aged < 6 yr), present with a unique form of disease and often have atypical features. METHODS: Whole-exome data for 147 pediatric patients with IBD were interrogated for a panel of 51 genes associated with monogenic IBD. Observed variation was categorized according to the American College of Medical Genetics (ACMG) guidelines to identify rare, novel, and known variants that might contribute to IBD. RESULTS: Five hundred seventy-four variants were identified across 51 genes. These were categorized in line with ACMG guidance to remove benign variants and to identify "pathogenic" and "likely pathogenic" variants. In 6 patients, we observed 6 pathogenic variants of which CYBA(c.287+2T>C), COL7A1(c.6501+1G>C), LIG4(p.R814X), and XIAP(p.T470S) were known causative mutations, and FERMT1(p.R271Q) and SKIV2L(c.354+5G>A) were novel. In the 3 patients with XIAP, SKIV2L, and FERMT1 variants, individuals' disease features resembled the monogenic phenotype. This was despite apparent heterozygous carriage of pathogenic variation for the latter 2 genes. The XIAP variant was observed in a hemizygous male. CONCLUSIONS: Whole-exome sequencing allows for identification of known and de novo potentially causative mutations in genes associated with monogenic IBD. Although these are rare conditions, it is vital to identify causative mutations early to improve prognosis. We postulate that in a subset of IBD, heterozygous mutations (in genes believed to manifest IBD through autosomal recessive inheritance) may contribute to clinical presentation.
BACKGROUND: Most cases of inflammatory bowel disease (IBD) are caused by complex host-environment interaction. There are a number of conditions associated with a single-gene mutation, most cases are very early onset (aged < 6 yr), present with a unique form of disease and often have atypical features. METHODS: Whole-exome data for 147 pediatric patients with IBD were interrogated for a panel of 51 genes associated with monogenic IBD. Observed variation was categorized according to the American College of Medical Genetics (ACMG) guidelines to identify rare, novel, and known variants that might contribute to IBD. RESULTS: Five hundred seventy-four variants were identified across 51 genes. These were categorized in line with ACMG guidance to remove benign variants and to identify "pathogenic" and "likely pathogenic" variants. In 6 patients, we observed 6 pathogenic variants of which CYBA(c.287+2T>C), COL7A1(c.6501+1G>C), LIG4(p.R814X), and XIAP(p.T470S) were known causative mutations, and FERMT1(p.R271Q) and SKIV2L(c.354+5G>A) were novel. In the 3 patients with XIAP, SKIV2L, and FERMT1 variants, individuals' disease features resembled the monogenic phenotype. This was despite apparent heterozygous carriage of pathogenic variation for the latter 2 genes. The XIAP variant was observed in a hemizygous male. CONCLUSIONS: Whole-exome sequencing allows for identification of known and de novo potentially causative mutations in genes associated with monogenic IBD. Although these are rare conditions, it is vital to identify causative mutations early to improve prognosis. We postulate that in a subset of IBD, heterozygous mutations (in genes believed to manifest IBD through autosomal recessive inheritance) may contribute to clinical presentation.
Authors: Lauren V Collen; David Y Kim; Michael Field; Ibeawuchi Okoroafor; Gwen Saccocia; Sydney Driscoll Whitcomb; Julia Green; Michelle Dao Dong; Jared Barends; Bridget Carey; Madison E Weatherly; Shira Rockowitz; Piotr Sliz; Enju Liu; Alal Eran; Leslie Grushkin-Lerner; Athos Bousvaros; Aleixo M Muise; Christoph Klein; Vanessa Mitsialis; Jodie Ouahed; Scott B Snapper Journal: J Crohns Colitis Date: 2022-09-08 Impact factor: 10.020
Authors: Eileen Crowley; Neil Warner; Jie Pan; Sam Khalouei; Abdul Elkadri; Karoline Fiedler; Justin Foong; Andrei L Turinsky; Dana Bronte-Tinkew; Shiqi Zhang; Jamie Hu; David Tian; Dalin Li; Julie Horowitz; Iram Siddiqui; Julia Upton; Chaim M Roifman; Peter C Church; Donna A Wall; Arun K Ramani; Daniel Kotlarz; Christoph Klein; Holm Uhlig; Scott B Snapper; Claudia Gonzaga-Jauregui; Andrew D Paterson; Dermot P B McGovern; Michael Brudno; Thomas D Walters; Anne M Griffiths; Aleixo M Muise Journal: Gastroenterology Date: 2020-02-19 Impact factor: 22.682
Authors: Holm H Uhlig; Fabienne Charbit-Henrion; Daniel Kotlarz; Dror S Shouval; Tobias Schwerd; Caterina Strisciuglio; Lissy de Ridder; Johan van Limbergen; Marina Macchi; Scott B Snapper; Frank M Ruemmele; David C Wilson; Simon P L Travis; Anne M Griffiths; Dan Turner; Christoph Klein; Aleixo M Muise; Richard K Russell Journal: J Pediatr Gastroenterol Nutr Date: 2021-03-01 Impact factor: 3.288
Authors: Derrick J Morton; Emily G Kuiper; Stephanie K Jones; Sara W Leung; Anita H Corbett; Milo B Fasken Journal: RNA Date: 2017-11-01 Impact factor: 4.942
Authors: Jodie Ouahed; Elizabeth Spencer; Daniel Kotlarz; Dror S Shouval; Matthew Kowalik; Kaiyue Peng; Michael Field; Leslie Grushkin-Lerner; Sung-Yun Pai; Athos Bousvaros; Judy Cho; Carmen Argmann; Eric Schadt; Dermot P B Mcgovern; Michal Mokry; Edward Nieuwenhuis; Hans Clevers; Fiona Powrie; Holm Uhlig; Christoph Klein; Aleixo Muise; Marla Dubinsky; Scott B Snapper Journal: Inflamm Bowel Dis Date: 2020-05-12 Impact factor: 5.325